References
- Rohatiner A ZS, Prior P F, Burton A C, Smith A T, Balkwii F R, Lister T A. Central nervous system of interferon. Br J Cancer 1983; 47: 419–422
- Meyers C A, Scheibel R S, Forman A D. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41: 672–676
- Meimsky O, Nisipeanu P, Loewenstein A, et al. Interferon-related cortical blindness. Cancer Chemother Pharmacol 1992; 29: 329–330
- Quesada J R, Hersh E M, Gutteman J V. Clinical toxicity of interferons in cancer patients. J Clin Oncol 1986; 4: 234–243
- Guyer D R, Tiedeman J, Yannuzzi L A, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993; 111: 350–356
- Bauherz G, Soeur M, Lustman F. Oculomotor nerve paralysis induced by alpha-II-interferon. Acta Neurol Belg 1990; 90: 111–114
- Riedel R R, Schmitt A, Hartmann A. Ocular pseudo-myasthenic reaction induced by interferon in an AIDS patient. Klin Wochenschr 1991; 69: 930–93i
- Pacifici L, Passarelli F, Papa G, Cannone L. Acute third cranial nerve ophthalmoplegia: possible pathogenesis from alpha-II-interferon treatment. Ital J Neurol Sci 1993; 14: 579–580
- Stalberg E, Sanders D B. Electrophysiological tests of neuromuscular transmission, E Stalberg, R R Young. Clinical Neurophysiology. Butterworths, London 1981; 88–116
- Glaser J S, Bachynski B. Disorders of the neuromuscular junction and ocular myopathies. Neuro-Ophthalmology2nd edition, J S Glaser. J.B. Lippincott, Philadelphia 1990; 392–406
- Uyama J, Mimura O, Ikeda N, Shimo-Oku M. Single-fiber electro-myography of extraocular muscles in myasthenia gravis. Neuro-opthalmology 1993; 13: 253–261
- Kelly J J, Dauble J R, Lennon V A, Howard F M, Younge B R. The laboratory diagnostic of mild myasthenia gravis. Ann Neurol 1982; 12: 238–242
- Miller N R. Myopathies and disorders of neuromuscular transmission. Walsh and Hoyt's Clinical Neuro-Ophthalmology4th edition. Williams & Wilkins, Baltimore 1985; 785–891
- Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety 1994; 10: 115–150